The drug candidate Apta-1 has in preclinical studies shown to counteract coagulation and reduce the risk of blood clotting, slow down the body's uncontrolled inflammatory response, repair or inhibit tissue degradation and modulate the body's own immune response. All of these mechanisms are relevant in the fight against sepsis, a multi factorial condition which can be triggered by several diseases and by a simple infection.
After the initial start up agreement the parties intend to sign a full agreement on performing the studies to keep the communicated timelines.
CEO Mikael Lindstam comments:
"After more than six months' dialogue with CHDR we have now found a good design for the phase 1 studies with Apta-1 where we have discussed several topics, such as an added tailor made study design for Apta-1. Primarily we will study safety in healthy volunteers but also a first indication of the effect of Apta-1. The effect part of the study is important to confirm an initial Proof of Concept (PoC) and risk assess the protocol for the phase 2 studies. I am very pleased with this design and CHDR has been an excellent discussion partner in finding the optimal study design for Apta-1."
For further information:
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Sepsis
Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In
* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR,
Forward-looking statements
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.
About Aptahem
https://news.cision.com/aptahem/r/aptahem-signs-start-up-agreement-with-international-clinical-cro-for-phase-1-studies-with-apta-1,c3482551
https://mb.cision.com/Main/12121/3482551/1517828.pdf
(c) 2022 Cision. All rights reserved., source